Preparation for International Cooperation on Cosmetics Regulation Eleventh Annual Meeting; Public Meeting, 17012-17013 [2017-06938]
Download as PDF
nlaroche on DSK30NT082PROD with NOTICES
17012
Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–1813 for ‘‘Antimicrobial Drugs
Advisory Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
VerDate Sep<11>2014
14:52 Apr 06, 2017
Jkt 241001
FOR FURTHER INFORMATION CONTACT:
Lauren D. Tesh, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533,
AMDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION
Agenda: The committee will discuss
the development of antibacterial drugs
that treat a single species of bacteria
when the target species infrequently
causes infections; examples of such
drugs include those that are only active
against Pseudomonas aeruginosa or
Acinetobacter baumannii.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see the ADDRESSES section) on
or before April 10, 2017, will be
provided to the committee. Oral
presentations from the public will be
scheduled between approximately 1:30
p.m. and 2:30 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
approximate time requested to make
their presentation on or before April 7,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 10, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Lauren D. Tesh
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 3, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2017–06901 Filed 4–6–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Preparation for International
Cooperation on Cosmetics Regulation
Eleventh Annual Meeting; Public
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public meeting.
The Food and Drug
Administration (FDA or we) is
announcing a public meeting entitled
‘‘International Cooperation on
Cosmetics Regulation (ICCR)—
Preparation for ICCR–11 Meeting.’’ The
purpose of the meeting is to invite
public input on various topics
pertaining to the regulation of
cosmetics. We may use this input to
SUMMARY:
E:\FR\FM\07APN1.SGM
07APN1
Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices
nlaroche on DSK30NT082PROD with NOTICES
help us prepare for the ICCR–11 meeting
that will be held July 12–14, 2017, in
Brasilia, Brazil.
DATES: The public meeting will be held
on May 25, 2017, from 2 p.m. to 4 p.m.
See the SUPPLEMENTARY INFORMATION
section for registration date and
information.
ADDRESSES: The public meeting will be
held at the Food and Drug
Administration, Center for Food Safety
and Applied Nutrition, 5001 Campus
Dr., Wiley Auditorium (first floor),
College Park, MD 20740.
FOR FURTHER INFORMATION CONTACT:
Jonathan Hicks, Office of Cosmetics and
Colors, Food and Drug Administration,
5001 Campus Dr. (HFS–125), College
Park, MD 20740, email: jonathan.hicks@
fda.hhs.gov, 240–402–1375.
SUPPLEMENTARY INFORMATION:
I. Background
The purpose of the multilateral
framework on the ICCR is to pave the
way for the removal of regulatory
obstacles to international trade while
maintaining global consumer protection.
The purpose of the meeting is to invite
public input on various topics
pertaining to the regulation of
cosmetics. We may use this input to
help us prepare for the ICCR–11 meeting
that will be held July 12–14, 2017, in
Brasilia, Brazil.
ICCR is a voluntary international
group of cosmetics regulatory
authorities from Brazil, Canada, the
European Union, Japan, and the United
States of America. These regulatory
authority members will enter into
constructive dialogue with their
relevant cosmetics industry trade
associations and public advocacy
groups. Currently, the ICCR members
are: The Brazilian Health Surveillance
Agency; Health Canada; the European
Commission Directorate-General for
Internal Market, Industry,
Entrepreneurship, and Small and
Medium-sized Enterprises; the Ministry
of Health, Labor, and Welfare of Japan;
and FDA. All decisions made by
consensus will be compatible with the
laws, policies, rules, regulations, and
directives of the respective
administrations and governments.
Members will implement and/or
promote actions or documents within
their own jurisdictions and seek
convergence of regulatory policies and
practices. Successful implementation
will need input from stakeholders.
II. Topics for Discussion at the Public
Meeting
We will make the agenda for the
public meeting available on the Internet
VerDate Sep<11>2014
14:52 Apr 06, 2017
Jkt 241001
at https://www.fda.gov/Cosmetics/
InternationalActivities/ICCR/
default.htm. Depending on the number
of requests for oral presentations, we
intend to have an agenda available by
May 18, 2017.
III. Participating in the Public Meeting
Registration: To register for the public
meeting, send registration information
(including your name, title, affiliation,
address, email, and telephone), to
Jonathan Hicks by May 11, 2017. If you
would like to listen to the meeting by
phone, please submit a request for a
dial-in number by May 11, 2017. If you
need special accommodations due to a
disability, please contact Jonathan Hicks
by May 18, 2016.
Requests for Oral Presentations: If you
wish to make an oral presentation, you
should notify Jonathan Hicks by May
11, 2017, and submit a brief statement
of the general nature of the evidence or
arguments that you wish to present,
your name, title, affiliation, address,
email, and telephone, and indicate the
approximate amount of time you need
to make your presentation. You may
present proposals for future ICCR
agenda items, data, information, or
views, in person or in writing, on issues
pending at the public meeting. There
will be no presentations by phone. Time
allotted for oral presentations may be
limited to 10 minutes or less for each
presenter.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
at https://www.regulations.gov. It may
also be viewed at the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20850.
Dated: April 3, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–06938 Filed 4–6–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct;
Correction
Office of the Secretary, HHS.
Correction of notice.
AGENCY:
ACTION:
This document corrects an
error that appeared in the notice
published in the June 8, 2016, Federal
Register entitled ‘‘Findings of Research
Misconduct.’’
DATES:
SUMMARY:
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
17013
Effective Date: April 7, 2017.
Applicability Date: The correction
notice is applicable for the Findings of
Research Misconduct notice published
on June 8, 2016.
FOR FURTHER INFORMATION CONTACT: Ms.
Karen Gorirossi at 240–453–8800.
SUPPLEMENTARY INFORMATION:
I. Background
In FR Doc. 2016–13541 of June 8,
2016 (81 FR 36932–36933), there was a
typographical error involving one of the
papers cited in the notice. The error is
identified and corrected in the
Correction of Errors section below.
II. Correction of Errors
In FR Doc. 2016–13541 of June 8,
2016 (81 FR 36932–36933), make the
following correction:
1. On page 36932, third column, in FR
Doc. 2016–13541, second to last
paragraph, line 5, change ‘‘August’’ to
‘‘December’’ so that the text reads
‘‘falsified twenty-four (24) fluorescent
image panels by drawing staining in
Photoshop and falsely labeling them in
Figures 5B, 5C, 5D, 5E, 7A, 7B, 7D, 8A,
8B, 9A, and 9B in the December 2015
Development paper and included some
of the same images in four (4) figures in
the ASCB 2015 poster and in two (2)
figures in the MARZ 2015 poster’’
Dated: March 30, 2017.
Kathryn Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–07006 Filed 4–6–17; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
Council of Councils.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the meeting will be
closed to the public in accordance with
E:\FR\FM\07APN1.SGM
07APN1
Agencies
[Federal Register Volume 82, Number 66 (Friday, April 7, 2017)]
[Notices]
[Pages 17012-17013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06938]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Preparation for International Cooperation on Cosmetics Regulation
Eleventh Annual Meeting; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing a
public meeting entitled ``International Cooperation on Cosmetics
Regulation (ICCR)--Preparation for ICCR-11 Meeting.'' The purpose of
the meeting is to invite public input on various topics pertaining to
the regulation of cosmetics. We may use this input to
[[Page 17013]]
help us prepare for the ICCR-11 meeting that will be held July 12-14,
2017, in Brasilia, Brazil.
DATES: The public meeting will be held on May 25, 2017, from 2 p.m. to
4 p.m. See the SUPPLEMENTARY INFORMATION section for registration date
and information.
ADDRESSES: The public meeting will be held at the Food and Drug
Administration, Center for Food Safety and Applied Nutrition, 5001
Campus Dr., Wiley Auditorium (first floor), College Park, MD 20740.
FOR FURTHER INFORMATION CONTACT: Jonathan Hicks, Office of Cosmetics
and Colors, Food and Drug Administration, 5001 Campus Dr. (HFS-125),
College Park, MD 20740, email: jonathan.hicks@fda.hhs.gov, 240-402-
1375.
SUPPLEMENTARY INFORMATION:
I. Background
The purpose of the multilateral framework on the ICCR is to pave
the way for the removal of regulatory obstacles to international trade
while maintaining global consumer protection. The purpose of the
meeting is to invite public input on various topics pertaining to the
regulation of cosmetics. We may use this input to help us prepare for
the ICCR-11 meeting that will be held July 12-14, 2017, in Brasilia,
Brazil.
ICCR is a voluntary international group of cosmetics regulatory
authorities from Brazil, Canada, the European Union, Japan, and the
United States of America. These regulatory authority members will enter
into constructive dialogue with their relevant cosmetics industry trade
associations and public advocacy groups. Currently, the ICCR members
are: The Brazilian Health Surveillance Agency; Health Canada; the
European Commission Directorate-General for Internal Market, Industry,
Entrepreneurship, and Small and Medium-sized Enterprises; the Ministry
of Health, Labor, and Welfare of Japan; and FDA. All decisions made by
consensus will be compatible with the laws, policies, rules,
regulations, and directives of the respective administrations and
governments. Members will implement and/or promote actions or documents
within their own jurisdictions and seek convergence of regulatory
policies and practices. Successful implementation will need input from
stakeholders.
II. Topics for Discussion at the Public Meeting
We will make the agenda for the public meeting available on the
Internet at https://www.fda.gov/Cosmetics/InternationalActivities/ICCR/default.htm. Depending on the number of requests for oral
presentations, we intend to have an agenda available by May 18, 2017.
III. Participating in the Public Meeting
Registration: To register for the public meeting, send registration
information (including your name, title, affiliation, address, email,
and telephone), to Jonathan Hicks by May 11, 2017. If you would like to
listen to the meeting by phone, please submit a request for a dial-in
number by May 11, 2017. If you need special accommodations due to a
disability, please contact Jonathan Hicks by May 18, 2016.
Requests for Oral Presentations: If you wish to make an oral
presentation, you should notify Jonathan Hicks by May 11, 2017, and
submit a brief statement of the general nature of the evidence or
arguments that you wish to present, your name, title, affiliation,
address, email, and telephone, and indicate the approximate amount of
time you need to make your presentation. You may present proposals for
future ICCR agenda items, data, information, or views, in person or in
writing, on issues pending at the public meeting. There will be no
presentations by phone. Time allotted for oral presentations may be
limited to 10 minutes or less for each presenter.
Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will be accessible at https://www.regulations.gov. It may also be viewed at the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20850.
Dated: April 3, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-06938 Filed 4-6-17; 8:45 am]
BILLING CODE 4164-01-P